Germline stem cell genes can promote The repair of DNA in the early stages of cancer

A study led by Gao Jianxin, a professor at the stem cell research center of renji hospital affiliated to Shanghai jiao tong university school of medicine, recently published in plos one, an international academic journal published in the United States, showed that the reproductive stem cell gene PIWIL2 plays an important role in the early development of tumors. Experts believe that the results of this study may provide a new way for the early prevention and treatment of cancer in the future.

The occurrence of tumor begins with genetic mutation after DNA damage in cells. Researchers such as Gao Jianxin from the stem cell research center of Shanghai renji hospital found that PIWIL2 gene was largely silent in cells when DNA was not damaged. When DNA damage is caused by acute radiation or chemical drugs, PIWIL2 gene will be temporarily activated to participate in the regulation of chromatin relaxation, chain unbinding, and promote DNA repair. The relaxation of the tight double stranded structure of cell chromatin is the key to the accurate and effective repair of chromatin by other proteins. After the repair, the PIWIL2 gene was restored to its original level. For defective cells, when the PIWIL2 gene is missing and cannot be successfully unlinked, the repair of DNA cannot be completed. At this point, the cells may go to senescence, apoptosis or transformation into tumor cells, and lose their control over cell division, leading to tumor formation.

Gao jianxin and other researchers believe that since this repair process is at the early stage of tumorigenesis, elucidating the role of PIWIL2 gene in DNA repair will provide a new perspective for in-depth study of the biological function of PIWIL2 gene and potential means of cancer prevention and treatment. In addition, Gao jianxin and others also believe that PIWIL2 gene may be used as a new biomarker in the future to detect and evaluate the injury caused by acute radiation.

Researchers from the Ohio state university general cancer center, the first affiliated hospital of Zhengzhou university and the department of radiation oncology at the university of California, Davis were involved in the study.
Related News